ReliantHeart Inc.

ReliantHeart, Inc. is a privately held American company headquartered in Houston, Texas that designs, manufactures, and provides remote monitoring capabilities for its left ventricular assist devices (LVAD, or VAD) which are used to assist circulation for failing hearts.

ReliantHeart Inc.
TypePrivate
IndustryMedical Devices
FoundedAugust 2013 (2013-08) in Houston, Texas, United States
Headquarters
Houston, Texas
Key people
  • Sailesh Saxena
  • Bryan E. Lynch
  • Anthony Williams
  • Cindy McKelroy
  • Rob Petterson
  • Jennifer Michael
Websitereliantheart.com

History

The original VAD was developed by David Saucier, a heart transplant patient who worked at NASA, and surgeon Michael DeBakey.[1][2] Dallas W. Anderson, who founded MicroMed Technology Inc. in 1995,[3] was granted exclusive rights to the NASA/DeBakey VAD in 1996.[4] MicroMed Cardiovascular, Inc. filed for Chapter 11 bankruptcy in June 2013,[5] and former members of the company founded ReliantHeart Inc. in August 2013.[6] ReliantHeart became successor-in-interest to the assets of MicroMed Cardiovascular, Inc., including the HeartAssist5 VAD.[7] In August 2014, ReliantHeart purchased 50% of INRTracker,[8] an online tool for patients taking Warfarin and reporting of INR.[9]

Products

The HeartAssist5 is a modern version of the DeBakey VAD[10] and as of December 2014 was the only remotely monitored medical device in the world.[8] It was first approved for use in Europe in 2009 under MicroMed Cardiovascular, Inc.[11] The HeartAssist5 is in use in Europe[10] as a destination therapy by patients who are not candidates to receive heart transplants and as a bridge to transplant for those who are.[12]

The HeartAssist5 is an axial flow pump and the smallest of the full-flow LVADs. Its pump is slightly larger in diameter than a U.S. quarter or one-Euro coin and weighs only 3.2 ounces (92 grams).[13] The small size allows for the device to be implanted adjacent to the heart and above the diaphragm; this is unique among LVADs.[14]

The aVAD is an intraventricular implant. It has the same blood path as the HeartAssist5 but also has active magnetic stabilization,[15] is smaller than the HeartAssist5, and operates with more efficiency and power.[16] The aVAD was approved for use in Europe in August 2016, and implantations were expected to begin as early as that September.[17]

Regulatory approval

CE Mark – The aVAD and the HeartAssist5 VAD are CE Mark-approved in Europe for use in patients requiring ventricular support due to end stage heart failure.[18][19][20]
IDE clinical trial – ReliantHeart Inc. was granted approval from the FDA to conduct an Investigational Device Exemption (IDE) Clinical Trial on the HeartAssist5® Ventricular Assist Device System for patients awaiting cardiac transplant.[21] The study began in September 2014. The University of Chicago Medicine implanted the HeartAssist5 into the first patient in the United States in March 2015.[12]

Innovation

True Flow Measurement The Flow Probe in the aVAD and HeartAssist5 is a tool to observe interaction between the device and the ventricle. This allows for clinicians to confirm that the aortic valve is opening as the ventricle is pressurized. The measurement is unaffected by changes in blood or fibrin deposition, which eliminates the need for estimation.[22]

Remote Monitoring is real time Machine to Machine (M2M) – devices communicating via data transmission and generating alerts based on the data transmitted. Through the HeartAssistRemote Monitoring System, patient data is relayed, using the Numerex Network, to a secured VADLink[23] website that can be accessed by the clinical team[24] and enables fast diagnosis regardless of patient location.[17]

The HeartAssistRemote Monitoring System received a 2014 M2M Telehealth Award from M2M Evolution Magazine.[23]

In development
  • Liberty system, with wireless Transcutaneous Energy Transfer (TET): ReliantHeart is collaborating with Dualis MedTech, and others, to develop this fully implantable system.[15] The Liberty system will be available for patients who already have a HeartAssist5 without exchanging the pump; this eliminates the possibility of driveline infection.[25] The companies are creating the system step by step and have indicated that the configuration will be compatible with future products that are introduced.[15]

References
  1. "NASA Engineer, Heart Patient, Had Major Role in Design of Heart Pump". NASA. 12 June 2000. Retrieved 16 February 2015.
  2. Noon, George P.; Joyce, David L. (2004). "THE MICROMED DEBAKEY VAD ® : A BRIDGE TO THE FUTURE". Journal of the Methodist Debakey Heart Center. 1: 9–11. doi:10.14797/mdcj-1-1-9.
  3. "Dallas Anderson". The Wall Street Transcript. Retrieved 16 February 2015.
  4. "Heart Assist Pump". NASA. Archived from the original on 20 August 1999. Retrieved 16 February 2015.
  5. "MicroMed Petition". Retrieved 16 February 2015.
  6. "Company Overview of ReliantHeart Inc".
  7. "ReliantHeart to manufacture, sell and support the HeartAssist5 VAD with Rodger Ford as CEO". Retrieved 16 February 2015.
  8. Martin, Joe (23 December 2014). "Houston health company raises millions, eyes IPO". Retrieved 16 February 2015.
  9. "INR Level Tool: What does this tool do?". INR Tracker. Retrieved 22 August 2016.
  10. "World's first new DeBakey heart assist device implanted successfully". The Free Library. Retrieved 16 February 2015.
  11. "Heidelberg cardiac surgeons implant world's first new DeBakey Heart Assist Device". EurekAlert. Retrieved 16 February 2015.
  12. "First HeartAssist5(R) VAD Implant Performed in the U.S". PR Web. 10 March 2015. Retrieved 23 August 2016.
  13. "ReliantHeart HeartAssist5". My LVAD. Retrieved 23 August 2016.
  14. Ahrends, Keenan (22 June 2012). "MicroMed Cardiovascular's HeartAssist 5 goes wireless". IoT Now. Retrieved 25 August 2016.
  15. Thibault, Marie (15 July 2016). "Details on ReliantHeart's Impressive LVAD Technology Cache". Medical Device and Diagnostic Industry. Retrieved 25 August 2016.
  16. aVAD
  17. "ReliantHeart's New, More Powerful and Efficient aVAD Pump Wins European Approval". MedGadget. 4 August 2016. Retrieved 25 August 2016.
  18. Walker, Chris (13 November 2013). "ReliantHeart expands CE Mark for HeartAssist5 ventricular assist device". Mass Device. Retrieved 23 August 2016.
  19. Thibault, Marie (2 August 2016). "Exclusive: ReliantHeart's aVAD gets CE Mark". Medical Device and Diagnostic Industry. Retrieved 23 August 2016.
  20. Comish, Chris (10 June 2014). "ReliantHeart Device HeartAssist 5 VAD Already Saving Lives in Europe". BioNews Texas. Retrieved 2 September 2016.
  21. "ReliantHeart Commences FDA Trial on HeartAssist5 VAD". ReliantHeart. 3 September 2014. Retrieved 2 September 2016.
  22. ""Transonic Inside" Ensures Adequate Flow through Life-Saving Devices". Transonic. Retrieved 23 August 2016.
  23. "Numerex Receives 2014 M2M Telehealth Award: Network Enabled HeartAssistRemote Honored for Improving Healthcare Delivery". 26 August 2014. Retrieved 25 August 2016.
  24. "Implantable Pump Helps the Failing Heart". HospiMedica International. 14 July 2014. Retrieved 25 August 2016.
  25. Sagolla, Stephan (7 April 2015). "Dualis MedTech and ReliantHeart Partner on Fully Implantable TET System for the HeartAssist5 LVAD" (PDF). Retrieved 2 September 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.